

Paolo Bironzo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3728804/publications.pdf>

Version: 2024-02-01

69
papers

1,576
citations

394421

19
h-index

345221

36
g-index

71
all docs

71
docs citations

71
times ranked

3280
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergency room comprehensive assessment of demographic, radiological, laboratory and clinical data of patients with COVID-19: determination of its prognostic value for in-hospital mortality. <i>Internal and Emergency Medicine</i> , 2022, 17, 205-214.	2.0	9
2	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 75.	8.6	7
3	Squamous cell histological transformation in a lung adenocarcinoma patient (hyper) progressing upon immunotherapy. <i>Tumori</i> , 2022, 108, NP15-NP19.	1.1	4
4	Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial. <i>Future Oncology</i> , 2022, 18, 1907-1915.	2.4	11
5	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103639.	4.4	13
6	Nutritional support in lung cancer: Time to combine immunonutrition with immunotherapy?. <i>Nutrition</i> , 2022, 98, 111637.	2.4	5
7	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, , 1.	2.8	1
8	Phase III study with atezolizumab versus placebo in patients with malignant pleural mesothelioma after pleurectomy/decortication (AtezoMeso study).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8591-TPS8591.	1.6	0
9	Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience. <i>Diagnostics</i> , 2022, 12, 1710.	2.6	4
10	Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer. <i>British Journal of Cancer</i> , 2021, 124, 281-289.	6.4	22
11	Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103189.	4.4	6
12	A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2021, 22, e63-e66.	2.6	22
13	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, e002421.		80
14	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103300.	4.4	6
15	Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 2564.	3.7	16
16	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 2332.	3.7	4
17	Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. <i>Cancers</i> , 2021, 13, 2425.	3.7	7
18	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	2.8	24

#	ARTICLE	IF	CITATIONS
19	Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era. <i>Lung Cancer</i> , 2021, 157, 85-91.	2.0	6
20	Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves. <i>JCO Oncology Practice</i> , 2021, 17, OP.21.00098.	2.9	3
21	Local for advanced, is this a paradox?. <i>Translational Lung Cancer Research</i> , 2021, 10, 3324-3328.	2.8	0
22	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 834-846.	2.8	7
23	Exploring the role of respiratory microbiome in lung cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103404.	4.4	18
24	Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102250.	7.7	6
25	Repositioning PARP inhibitors in the treatment of thoracic malignancies. <i>Cancer Treatment Reviews</i> , 2021, 99, 102256.	7.7	7
26	Winds From the ORIENT: New Data to Inform RATIONAL Choice?. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1434-1436.	1.1	0
27	Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. <i>Cancer Treatment Reviews</i> , 2021, 101, 102308.	7.7	21
28	Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12C" Patients. <i>Cancers</i> , 2021, 13, 6332.	3.7	10
29	Wnt/IL-1 ² /IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. <i>International Journal of Cancer</i> , 2020, 146, 192-207.	5.1	29
30	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. <i>Lung Cancer</i> , 2020, 139, 47-54.	2.0	28
31	SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit. <i>Frontiers in Oncology</i> , 2020, 10, 1722.	2.8	5
32	Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules. <i>Journal of Thoracic Oncology</i> , 2020, 15, e170-e172.	1.1	4
33	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	4.2	60
34	Future perspectives from lung cancer pre-clinical models: new treatments are coming?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2629-2644.	2.8	3
35	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer? a literature review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2674-2685.	2.8	2
36	Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won. <i>Translational Lung Cancer Research</i> , 2020, 9, 2545-2556.	2.8	13

#	ARTICLE	IF	CITATIONS
37	First-line immune-chemotherapy combination: the right strategy to fight squamous non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 546-549.	2.8	3
38	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2226-2231.	7.1	29
39	Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?. <i>Journal of Thoracic Oncology</i> , 2019, 14, e38-e40.	1.1	10
40	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1458-1471.	1.1	41
41	New emerging targets in cancer immunotherapy: the role of VISTA. <i>ESMO Open</i> , 2019, 4, e000683.	4.5	24
42	Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. <i>Future Oncology</i> , 2019, 15, 2543-2553.	2.4	10
43	Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. <i>Nature Biotechnology</i> , 2019, 37, 55-63.	17.5	203
44	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019, 51, 10-23.	0.9	5
45	Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?. <i>Annals of Translational Medicine</i> , 2019, 7, S212-S212.	1.7	5
46	Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 21-28.	4.4	15
47	Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?. <i>Future Oncology</i> , 2018, 14, 1223-1231.	2.4	8
48	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	3.1	13
49	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. <i>OncImmunology</i> , 2018, 7, e1398874.	4.6	41
50	NIBIT-MESO-1: limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study. <i>Journal of Thoracic Disease</i> , 2018, 10, S3878-S3881.	1.4	0
51	A review of guidelines for lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1556-S1563.	1.4	64
52	Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in <i>BAP1</i> or other DNA repair genes. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 573-583.	2.8	43
53	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changinâ€™™. <i>Clinical Lung Cancer</i> , 2018, 19, 461-463.	2.6	2
54	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 771-781.	10.7	167

#	ARTICLE	IF	CITATIONS
55	Biases in assessment and reporting of health-related quality of life (QoL): A systematic review of oncology randomized phase III trials published between 2012 and 2016.. Journal of Clinical Oncology, 2018, 36, e18719-e18719.	1.6	0
56	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. Tumori, 2017, 103, 405-421.	1.1	52
57	Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. Cancer Research and Treatment, 2017, 49, 834-845.	3.0	12
58	MET exon 14 mutation: another actionable genomic variation in patients with advanced NSCLC. Translational Cancer Research, 2016, 5, S101-S105.	1.0	1
59	Raising the bar for enthusiasm when looking at results of randomized phase II trials-the case of sunitinib in small-cell lung cancer. Translational Lung Cancer Research, 2016, 5, 89-91.	2.8	1
60	Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study. Journal of Thoracic Oncology, 2015, 10, 492-499.	1.1	142
61	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treatment Reviews, 2015, 41, 884-892.	7.7	141
62	How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?. , 2015, , 49-66.		0
63	Squamous carcinoma of the lung: still a long and winding road to successful treatment. Lung Cancer Management, 2014, 3, 365-368.	1.5	0
64	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 1495-1513.	2.4	8
65	Next-generation sequencing in malignant pleural mesothelioma: A retrospective study.. Journal of Clinical Oncology, 2014, 32, 7530-7530.	1.6	0
66	Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. Cancer Treatment Reviews, 2013, 39, 966-973.	7.7	37
67	Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: A monocentric study. Tumori, 2012, 98, 451-457.	1.1	6
68	DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. DNA Repair, 2012, 11, 374-380.	2.8	28
69	Achievements in targeted therapies. , 0, , 215-233.		0